S&P Futures
3,902.00 +4.25 (+0.11%) Dow Futures
31,241.00 +39.00 (+0.12%) Nasdaq Futures
11,838.00 -40.25 (-0.34%) Russell 2000 Futures
1,771.50 -3.40 (-0.19%) Crude Oil
110.35 +0.46 (+0.42%) Gold
1,845.10 +3.90 (+0.21%)
Pulse Biosciences, Inc. (PLSE)
Chart Events
Performance Outlook
| Previous Close | 2.1400 |
| Open | 2.2300 |
| Bid | 1.7500 x 2200 |
| Ask | 2.0000 x 900 |
| Day's Range | 1.9500 - 2.2300 |
| 52 Week Range | 1.4050 - 29.1600 |
| Volume | |
| Avg. Volume | 254,001 |
| Market Cap | 58.966M |
| Beta (5Y Monthly) | 1.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.3050 |
| Earnings Date | Feb 21, 2022 - Feb 25, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.50 |
- Business Wire
Pulse Biosciences, Inc. Announces Changes to its Rights Offering
HAYWARD, Calif., May 19, 2022--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a novel bioelectric medicine company commercializing the CellFX® System Powered by Nano-Pulse Stimulation™ (NPS™) technology, announced today two changes to its current rights offering. First, the Company has extended the expiration date of the rights offering from May 23, 2022 to May 26, 2022, at 5:00 p.m., Eastern Time (the "Expiration Date"). Second, the Company has amended the defini
- American City Business Journals
Stock rebound uncertain for U.S. biotechs as risks multiply for investors
U.S. biotechs and other health care stocks accounted for about 11% of all losses in U.S. equity values during the five-month period analyzed by The Business Journals.
- Zacks
Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates
Pulse Biosciences, Inc (PLSE) delivered earnings and revenue surprises of 5.88% and 36.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
